The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer - Trial NCT06283875
Access comprehensive clinical trial information for NCT06283875 through Pure Global AI's free database. This phase not specified trial is sponsored by Geneplus-Beijing Co. Ltd. and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Geneplus-Beijing Co. Ltd.
Timeline & Enrollment
N/A
Mar 01, 2024
Jan 30, 2029
Primary Outcome
DFS of enrolled patients for 2 years
Summary
This study plans to enroll 80 patients with locally advanced cervical cancer (stage IB-ⅣA)
 confirmed by histology or cytology (according to the 2018 FIGO staging standard), who are
 expected to receive surgical resection or curative radiotherapy and chemotherapy. Collect
 baseline tumor tissue samples from patients during the treatment period, as well as
 peripheral blood samples (20 ml/time) from multiple treatment timepoints. Mutations in tumor
 tissue were detected by the 1021 genes panel, then personalized MRD monitoring probes were
 customized for patients, allowing for multi node peripheral blood sample ctDNA detection of
 enrolled patients. The clinical significance of ctDNA in prognostic stratification,
 recurrence monitoring, and efficacy prediction in surgical/non-surgical cervical cancer
 patients was explored. And compare the consistency and differences between ctDNA detection
 technology, imaging, and blood tumor markers in monitoring tumor disease progression, and
 evaluate the correlation between ctDNA status after curative treatment and patient PFS and
 RFS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06283875
Non-Device Trial